Baijin Life Science Holdings (01466) published its monthly return as of October 31, 2025. The authorized share capital remained at 10,000,000,000 ordinary shares with a par value of HKD 0.02, preserving total authorized capital at HKD 200,000,000.

The number of issued shares (excluding treasury shares) increased from 772,391,072 in the previous month to 892,254,085 as of October 31, 2025, marking a rise of 119,863,013 shares. This increase was attributed to the conversion of a convertible bond with a principal amount of HKD 31,500,000 at a conversion price of HKD 0.2628. As a result, 119,863,013 new ordinary shares were issued, with no additional movements in treasury shares reported.